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Abstract
Down syndrome (DS) results from trisomy of human chromosome 21 (Hsa21) and is associated with an increased risk of Alzheimer’s
disease (AD). Here, using the unique transchromosomic Tc1 mouse model of DS we investigate the influence of trisomy of Hsa21 on the
protein tau, which is hyperphosphorylated in Alzheimer’s disease. We show that in old, but not young, Tc1 mice increased phosphorylation
of tau occurs at a site suggested to be targeted by the Hsa21 encoded kinase, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase
1A (DYRK1A). We show that DYRK1A is upregulated in young and old Tc1 mice, but that young trisomic mice may be protected from
accumulating aberrantly phosphorylated tau. We observe that the key tau kinase, glycogen synthase kinase3- (GSK-3) is aberrantly
phosphorylated at an inhibitory site in the aged Tc1 brain which may reduce total glycogen synthase kinase3- activity. It is possible that
similar mechanism may also occur in people with DS.
2012 Elsevier Inc.
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Down syndrome (DS) is the most common cause of
genetic intellectual disability and is associated with an in-
creased risk of Alzheimer’s disease (AD). Between 30%
and 70% of people aged 60 years or older who have DS
develop AD (Wiseman et al., 2009). The life expectancy of
people who have DS has significantly increased in the last
20 years and hence so has the incidence of AD in this
population (Glasson et al., 2002). The onset of AD in people
who have DS is characterized by personality changes and
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Open access under CC BY license.executive dysfunction (Ball et al., 2006). The neuropatho-
logical changes associated with AD are similar in people
with and without DS (Mann, 1988). These changes included
the deposition of amyloid plaques composed of amyloid-
beta (A) peptides and neurofibrillary tangles (NFT) that
re formed of hyperphosphorylated tau. Genetic variations
n the tau gene, microtubule associated protein tau (MAPT),
re a risk factor for the age of onset of AD in people with
S (Jones et al., 2008). This may promote the formation of
FT and may play a role in the pathogenesis of AD in
eople with DS (Flament et al., 1990).
DS is caused by trisomy of chromosome 21 on which
42 protein encoding genes are found (www.ensembl.org,
elease 59). Hence trisomy of some of these genes results in
n increased risk of AD, as is observed in people who have
S, perhaps by promoting the aberrant phosphorylation of
au. Moreover, aberrant phosphorylation of tau has also
een reported in trisomic Ts65Dn and Ts1Cje, mice that
odel aspects of DS (Liu et al., 2008; Shukkur et al., 2006).
i
y
(
r
e
D
t
a
m
D
e
c
a
r
a
a
p
A
p
d
o
P
c
m
A
d
m
p
m
f
t
a
(
o
G
m
n
D
h
a
e
H
t
t
l
b
s
b
m
p
D
o
t
t
S
i
m
a
m
p
c
o
a
828.e32 O. Sheppard et al. / Neurobiology of Aging 33 (2012) 828.e31–828.e44Amyloid precursor protein (APP) is encoded on human
chromosome 21 (Hsa21); trisomy of this gene is likely to
contribute to the onset of AD in people with DS. Pathogenic
APP species, associated with AD are proposed to interact
with tau to exacerbate disease associated phenotypes (Daw-
son et al., 2010; Roberson et al., 2007). The Tc1 mouse
model that was used in this study is not functionally tri-
somic for APP because of a genomic rearrangement in
Hsa21 that is present in all Tc1 mice (S. Gribble, Wellcome
Trust, Sanger Institute, personal communication, and Sup-
plementary Fig. S1). Therefore in this study we are able to
investigate the effect of Hsa21 trisomy on tau in absence of
any potential influence of APP trisomy.
A number of recent studies have suggested that trisomy
of the Hsa21-encoded, proline-directed kinase DYRK1A,
which is expressed in fetal and adult brain, may contribute
to the aberrant phosphorylation of tau (Martí et al., 2003).
People trisomic for Hsa21 express elevated levels of
DYRK1A and exhibit increased DYRK1A kinase activity in
their brains (Dowjat et al., 2007; Liu et al., 2008; Lockstone
et al., 2007; Wegiel et al., 2008). In vitro, tau is phosphor-
ylated at Thr212 by DYRK1A (Liu et al., 2008; Woods et
al., 2001). This site is hyperphosphorylated in patients with
AD, and may contribute to disease pathogenesis (Mor-
ishima-Kawashima et al., 1995). Phosphorylation at this site
also primes tau for further phosphorylation at additional
sites by other kinases, such as glycogen synthase kinase3-
(GSK-3) (Woods et al., 2001). Overexpression of DYRK1A
n transgenic mouse models results in elevated phosphor-
lation of tau at a number of sites, and RNA interference
RNAi) knockdown of DYRK1A expression results in
educed phosphorylation of tau in cultured cells (Azorsa
t al., 2010; Liu et al., 2008; Ryoo et al., 2007).
YRK1A is found in the cytosol of cells and colocaliza-
ion of NFT and DYRK1A has been reported (Martí et
l., 2003; Wegiel et al., 2004). Thus, trisomy of DYRK1A
ay contribute to the early onset of AD in people with
S via an effect on tau phosphorylation.
The trisomy of Hsa21 encoded genes might also have an
ffect on the expression and activity of kinases encoded by
hromosomes other than Hsa21. For example, increased
bundance of cyclin-dependent kinase 5 (CDK5) has been
eported in the brains of young Ts65Dn mice that model
spects of DS (Pollonini et al., 2008). Alterations in the
ctivity of GSK-3 and CDK5 have been linked to hyper-
hosphorylation of tau and may contribute to the onset of
D (Noble et al., 2003). Also, decreased activity of phos-
hatases such as protein phosphatase 2A (PP2A), that can
ephosphorylate tau, have been associated with the devel-
pment of AD in people who have DS (Liang et al., 2008).
erturbations of these proteins in people with DS may
ontribute to the pathogenesis of AD.
To investigate the effect of trisomy of Hsa21 on the
olecular mechanisms that underlie the pathogenesis of
D, we have studied the phosphorylation of tau and abun-ance of key regulators of tau phosphorylation in a unique
ouse model of DS in both young and aged animals. The
hosphorylation of tau has been previously studied in DS
ouse models which are trisomic for approximately 55% or
ewer Hsa21 genes. The Tc1 mouse model of DS, used in
his study, contains a freely-segregating copy of Hsa21 in
ddition to a full complement of mouse chromosomes
O’Doherty et al., 2005) and is trisomic for more than 75%
f Hsa21 protein encoding genes, including DYRK1A (S.
ribble, Wellcome Trust, Sanger Institute, personal com-
unication). The Tc1 mouse model exhibits numerous phe-
otypes that resemble those observed in people who have
S, including deficits in long term potentiation (LTP) in the
ippocampus and learning and memory problems (Alford et
l., 2010; Dunlevy et al., 2010; Galante et al., 2009; Morice
t al., 2008; O’Doherty et al., 2005; Reynolds et al., 2010).
ere we study tau phosphorylation and associated regula-
ors in the most genetically complete mouse model of Hsa21
risomy used to address these issues to date.
In aged Tc1 mice we see an increase in the phosphory-
ation of tau at Thr212 but that there is no such change in the
rains of young Tc1 mice. Our results show that the expres-
ion of DYRK1A, a proposed tau kinase, is elevated in the
rains of young adult and old Tc1 mice. Thus young Tc1
ice appear to be protected from accumulating aberrantly
hosphorylated tau despite having elevated levels of
YRK1A. We also observe an increase in phosphorylation
f GSK-3 at Ser9 in aged but not young Tc1 mice.
GSK-3 is a key contributor to the hyperphosphorylation of
au and may be important to the phosphorylation of tau in
he context of Hsa21 trisomy (Cohen and Frame, 2001;
utherland et al., 1993). Supporting the observed alteration
n phosphorylation of GSK-3 at Ser9 we show that v-akt
urine thymoma viral oncogene homolog (AKT) exhibits
n increase in phosphorylation in the brains of aged Tc1
ice. AKT is an upstream regulator of GSK-3 Ser9 phos-
horylation and the change we see has been previously
orrelated with increased activity of this kinase. Therefore
ur data suggest the novel finding that Hsa21 trisomy may
lter the activity of GSK-3 in an age-dependent manner.
This mechanism may also occur in people with DS.
2. Methods
2.1. Animal welfare
Mice were housed in controlled conditions in accordance
with guidance issued by the Medical Research Council in
Responsibility in the Use of Animals for Medical Research
(1993) and all experiments were carried out under License
from the UK Home Office and with Local Ethical Review
panel approval.
2.2. DNA extraction and genotyping
DNA was extracted from tail tip (approximately 3 mm)
or ear biopsy from all samples analyzed by either the
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828.e33O. Sheppard et al. / Neurobiology of Aging 33 (2012) 828.e31–828.e44hot sodium hydroxide and tris (HOTSHOT) method (Truett
et al., 2000) or the proteinase K method. For the proteinase
K method tissue is lysed overnight using proteinase K
digestion in nuclei lysis buffer (Promega, Madison, WI,
USA), plus 0.12 M ethylenediaminetetracetic acid (EDTA)
at 55 °C. Proteins are precipitated from the resultant lysate
by addition of protein precipitation solution (Promega).
DNA is then precipitated with isopropanol and resuspended
in DNase free water. Tc1 mice were genotyped using poly-
merase chain reaction (PCR) (Tc1-specific primers forward:
5=-GGTTTGAGGGAACACAAAGCTTAACTCCCA-3=; re-
erse: 5=-ACAGAGCTACAGCCTCTGACACTATGAACT-
=; control primers forward: 5=- TTACGTCCATCGTGGA-
AGCAT-3=; reverse: 5=-TGGGCTGGGTGTTAGTCTTAT-
=).
Tc1 mice were taken from a colony maintained by mat-
ng Tc1 females to F1(129S8  C57BL/6) males. Presence
f the human DYRK1A in the Tc1 mice was checked by
CR of genomic DNA using primers specific to human
YRK1A sequence (forward 1: 5=- ATCCTCCTCGG-
AAGAAGCC-3=, reverse 1: 5=-GTGCATTGTCCTTGC-
AATC-3=; forward 2: 5=-AGCCGAGGAGAGACTGAG-
AG-3=; reverse 2 5=-AGCCGGCCCCATTTTCTTAAC
3=).
.3. Sequencing
PCR products were purified using QIAquick PCR puri-
cation kit (Qiagen, Sussex, UK) prior to automated fluo-
escence sequencing using a BigDye Terminator Ready
eaction Kit (Applied Biosystems, Carlsbad, CA, USA) on
3130XL Genetic Analyser (Applied Biosystems) accord-
ng to manufacturer’s protocols.
.4. RNA extraction and reverse transcription-PCR
RNA was extracted from whole brains from adult Tc1
nd age- and sex-matched euploid controls. Total RNA was
xtracted using TRIzol reagent (Invitrogen, Paisley, UK),
recipitated as per manufacturer’s instructions and resus-
ended in DNase- and RNase-free water. Amounts of RNA
ere equalized and complementary DNA was generated
sing a standard reverse-transcription protocol using ran-
om primers (Promega), Superscript II (Invitrogen), First
trand buffer (Invitrogen), and Deoxynucleotide Triphos-
hates (Promega). PCR using primers which amplify a
roduct from both mouse Dyrk1A and human DYKR1A
ranscripts (forward: 5=- GGAGAGACTTCAGCATG-
AAAC-3=; reverse: 5=-GCTGGGTCACGGAAGGTTTG-
=) and PCR using primers designed to raised a product
gainst human but not mouse Dyrk1a (forward: 5=-CAA-
AAAACAGCTGATGAAGG-3=; reverse 1: 5=-GCC-
CTGGGCGATTCTGG-3=; reverse 2: 5=-GATACGGTC-
TTCTAAAGGC-3=) were used. Similarly PCR primers
esigned to raise a product against human but not mouse
PP (exon 9 forward 2: 5=-AGCCAAAGAGAGGCTTGAG-
=; exon 15 reverse: 5=- CGGGCATCAACAGGCTCAA-3=; mxon 14 forward 1: 5=- CTCTCATGCCATCTTTGACC-3=;
xon 18 reverse 5: 5=- CTGCTCAAAGAACTTGTAG-3=)
ere used.
.5. Tissue preparation and Western blotting
For analysis of DYRK1A abundance in hippocampus
nd cortex, Tc1 and aged- and sex-matched wild type lit-
ermate samples were dissected under ice cold phosphate
uffered saline (PBS) before homogenization in radioim-
unoprecipitation assay buffer (150 mM sodium chloride,
0 mM Tris, 1% nonidet-40, 0.5% sodium deoxycholate,
.1% sodium dodecyl sulfate (SDS) plus complete protease
nhibitors (Roche Applied Science, Basel, Switzerland) by
echanical disruption using a Dounce homogenizer. For
iochemical analysis of all other proteins, hippocampus and
ortex of Tc1 and age- and sex-matched wild type littermate
ice were dissected in freshly prepared dissection buffer
10 mM Tris, 320 mM sucrose, 2 mM EDTA, 0.025%
aN3, 0.2 mM phenylarsine oxide, 0.1 mM ammonium
molybdate, 50 mM sodium fluoride, 2 mM sodium or-
thovanadate, and 10 mM sodium pyrophosphate) on ice, as
described in Plattner et al. (2006). All samples were col-
lected between hour 1 and hour 6 of the light cycle (standard
12-hour dark, 12-hour light cycle). Individual samples of
hippocampus or cortex were then homogenized on ice in P2
buffer (10 mM Tris, 320 mM sucrose, 2 mM EDTA,
0.025% NaN3, 0.4 mM phenylarsine oxide, 0.2 mM ammo-
nium molybdate, 100 mM sodium fluoride, 4 mM sodium
orthovanadate, and 20 mM sodium pyrophosphate) plus
complete protease inhibitors (Roche Applied Science) by
mechanical disruption using a Dounce homogenizer. Total
protein content was determined by DC Protein Assay (ra-
dioimmunoprecipitation assay buffer samples) or Bradford
assay (P2 buffer samples) (Bio-Rad, Hemel Hempstead,
UK). Samples from individual animals were run separately
and were not pooled.
Equal amount of total brain proteins were then denatured
in SDS denaturing buffer (Invitrogen) and -mercaptoeth-
nol for 10 minutes at 100 °C, prior to separation by SDS-
olyacrylamide gel electrophoresis using precast 4%–20%
ris-glycine gels (Invitrogen). Proteins were transferred to
itrocellulose membrane prior to blocking in 5% milk tris
uffered saline (TBS) (50 mM Tris, 150 mM NaCl, pH 7.6)
or 1 hour before incubating overnight with primary anti-
ody diluted in 1% bovine serum albumin (BSA)/TBS at
°C. After washing in TBST (50 mM Tris, 150 mM NaCl,
.05% Tween 20, pH 7.6) membranes were incubated with
n infrared-dye (800 and 680 CW) conjugated goat, anti-
ouse and anti-rabbit, secondary antibodies (Li-Cor Odys-
ey, Lincoln, NE, USA) for 1 hour in the dark, prior to
maging using an Odyssey Infrared Imaging System. Signal
integrated intensity) was measured from manually assigned
ands. See-Blue plus 2 (Invitrogen) or Odyssey Protein
olecular weight markers (Li-Cor Odyssey) was used as a
olecular weight marker. For total tau, total AKT, and total
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828.e34 O. Sheppard et al. / Neurobiology of Aging 33 (2012) 828.e31–828.e44GSK-3 measurements nitrocellulose membranes previ-
ously incubated with PHF1, AT8, Tau-threonine212,
GSK-3 phospho-serine9, GSK-3 phosphor-tyrosine216,
nd AKT phosphor-serine473 were stripped of primary and
econdary antibody signal by washing for 30 minutes in
tripping solution (2% SDS, 0.007% -mercaptoethanol,
hosphate-buffered saline), prior to blocking in 5% milk
BS and incubation with the new primary antibody. Simi-
arly blots probed with antibodies against DYRK1A, protein
hosphatase (PP1), PP2Acat and PP2A (PR65) were
tripped and reprobed with control anti--actin, anti-
APDH or anti--tubulin antibodies. Linearity of all anti-
bodies was confirmed by a 2-fold dilution series of eup-
loid and Tc1 cortical samples. Relative signal of antibody
of interest compared with the internal control was then
calculated, and relative signal was then normalized to
mean relative signal of littermate sex-matched control
samples.
Primary antibodies against DYRK1A (7D11, Abnova,
Taipei City, Taiwan) 1/500, pantau (DAKO, Glostrup, Den-
mark) 1/1600, phospho-tau Ser396/404 (PHF1, kind gift of
P. Davies) 1/100; phospho-tau Ser202/Thr205 (AT8,
Thermo Scientific, Loughborough, UK) 1/100, phospho-tau
Thr212 (Invitrogen) 1/100, PP1 (E-9, Santa Cruz, Santa
Cruz, CA, USA) 1/1000, PP2A (PR65A) (kind gift of S.M.
Dilworth) 1/250, PP2Acat (kind gift of S.M. Dilworth)
1/1000, pan-GSK-3 (BD Biosciences, Oxford, UK)
1/5000, phospho-GSK-3 Ser9 (Cell Signaling Technolo-
ies, Boston, MA, USA) 1/1000, phospho-GSK-3 Tyr216
BD Biosciences) 1/1000, CDK5 (Millipore, Billerica, MA,
SA) 1/2000, p35/p25 (Santa Cruz) 1/200, total-AKT (Cell
ignaling Technologies) 1/100, phospho-AKT Ser473 (Cell
ignaling Technologies) 1/250, -actin (Sigma, St Louis,
MO, USA) 1/80,000, Glyceraldehyde 3-phosphate dehydro-
genase (Abcam, Cambridge, UK) 1/20,000, -tubulin
Sigma) 1/10,000, were used at the concentrations indi-
ated. We note that linearity of antibody binding signal for
ll antibodies, was confirmed. A dilution series of Tc1 and
uploid control cortical total proteins was used for this.
.6. Immunohistochemistry
Whole brains of Tc1 and age- and sex-matched wild type
ittermate mouse were fixed by immersion in 10% buffered
ormal saline (Pioneer Research Chemicals Colchester, Es-
ex, UK) for a minimum of 48 hours. Following further
ashing for 24 hours in 10% buffered formal saline, tissue
amples were processed and embedded in paraffin wax.
ections were cut at a thickness of 5 m. After dewaxing
ections were pretreated by protease digestion. Staining
ith anti-tau antibodies was undertaken using a Ventana
utomated immunohistochemical staining machine (Ven-
ana Medical Systems, Tuscon, AZ, USA) as described
reviously (Wadsworth et al., 2008). A biotinylated-anti-
abbit IgG secondary antibody (iView SA-HRP, Ventanaedical Systems) was used before development with 3=3 biaminobenzedine tetrachloride as the chromogen (iView
AB, Ventana Medical Systems). Hematoxylin was used as
he counterstain.
.7. Statistical analysis
Data were analyzed by analysis of variance (ANOVA),
xed factors; genotype of mouse (Tc1 vs. control), age of
ouse (2 months vs. 20 months of age), and tissue sampled
hippocampus vs. cortex). No significant effect of tissue
ampled was found in the analysis therefore a further
NOVA, fixed factors; genotype of mouse (Tc1 vs. control)
nd age of mouse (2 months vs. 20 months of age) was
ndertaken. For significant fixed factors (p  0.05) a post
hoc comparison (the Fisher’s least significant difference
test) was applied.
3. Results
3.1. Age-dependent increase in tau phosphorylation in
Tc1 mice
To determine if trisomy of chromosome 21 alters the
phosphorylation of tau, we assayed a number of tau sites
that are aberrantly phosphorylated in AD. We studied 3
phospho-tau-specific antibodies in detail; PHF1 (Ser396/
Ser404), AT8 (Ser202/Thr205), and Thr212 (Thr212);
that recognize sites that are conserved in both mouse and
human tau. Phospho-tau-specific signal was normalized
against total tau signal. Young mice aged 2 months and
old mice aged 20 months were studied as indicated. The
total tau levels detected did not differ between the brains
of Tc1 and control euploid mice (Supplementary Fig.
S2). Low abundance of tau phosphorylated at sites rec-
ognized by PHF1, AT8, or Thr212 antibodies was de-
tected in the hippocampus of young Tc1 and control
mice, aged 2 months. No significant increase in tau phos-
phorylated at these sites was detected in the hippocampus
of young Tc1 mice, compared with matched wild type
littermate controls (Fig. 1A, B, C).
An increase in tau phosphorylated at Thr212 was ob-
served in the hippocampus of old Tc1 mice compared with
aged matched control mice and also young Tc1 mice, by
Western blot (ANOVA genotype  age F(1,51)  6.110;
p  0.017; post hoc least significant difference [LSD] test
old Tc1 compared with old control p  0.017, and young
Tc1 compared with old Tc1 p  0.04) (Fig. 1D). No sig-
nificant increase in phosphorylation of tau recognized by
PHF1 and AT8 was observed in old Tc1 hippocampus;
although a trend to increased phosphorylation at the PHF1
site was observed (Fig. 1E and F). An increase in Thr212
signal was detected in the cortex of Tc1 mice aged 20
months compared with aged-matched control mice (post
hoc LSD test p  0.04) (Fig. 2). Thus in old Tc1 mice
levated phosphorylation of tau at Thr212 occurs in the
rain. This suggests that trisomy of Hsa21 leads to the
h
h
b
s
828.e35O. Sheppard et al. / Neurobiology of Aging 33 (2012) 828.e31–828.e44accumulation of aberrantly phosphorylated tau in the ab-
sence of any additional copies of APP.
These data indicate that in the aged Tc1 brain abnor-
mal phosphorylation of tau occurs, which may promote
the formation of NFT. To determine if NFT or other tau
aggregates occur in the brains of aged Tc1 mice, sections
of Tc1 brain were stained with Thr212 and PHF1 anti-
bodies (Supplementary Fig. S3). No significant staining
in the brain could be detected using PHF1 or anti-tau
Thr212 antibodies in old Tc1 or wild type littermate
Fig. 1. Tau is aberrantly phosphorylated at threonine 212 in the hippocam
tau was investigated by Western blot of total hippocampal protein lysates u
(C) and (F). Equal amounts of total protein were loaded per lane and
phospho-tau/total-tau signal was determine for each Tc1 sample and co
nontranschromosomic control, in both young (2 months of age) and old (20
(ANOVA) including the fixed factor of tissue type (hippocampus or cortex
tissues was combined for subsequent analysis. A further ANOVA using fi
age or 20 months of age) was performed. Tau Thr212 (normalized to total
age (F(1,51)  6.110; p  0.17). Post hoc tests showed that a significant
compared with age- and sex-matched nontranschromosomic littermate co
ippocampus compared with young Tc1 hippocampus (LSD p  0.04; n 
ippocampus of young Tc1 mice compared with age- and sex-matched co
y AT8 or PHF1 was detected in aged or young Tc1 hippocampus compa
tandard error of the mean.control mice. A previous study has demonstrated that noNFT could be detected using anti-tau antibody AT8
(O’Doherty et al., 2005). These data suggest that the
aberrant phosphorylation of tau in brains of old Tc1 mice
does not trigger the formation of NFT or detectable
aggregates of tau in brain.
3.2. The levels of the phosphatases, PP2A, and PP1, are
not altered in the Tc1 mouse
To further understand the phosphorylation status of tau
in the context of chromosome 21 trisomy we investigated
ged but not young Tc1 mice. The abundance of phosphorylated forms of
i-phospho-tau antibodies Thr212 (A) and (D), AT8 (B) and (E), and PHF1
tal tau and -actin antibodies were used as controls (A–F). Relative
with the phospho-tau/total-tau ratio detected in the matched littermate
of age) animals. Normalized signals were analyzed by analysis of variance
o significant effect of tissue was observed therefore data for both types of
tors genotype of mouse (Tc1 or control) and age of mouse (2 months of
nal was significantly affected by the interaction of genotype of mouse 
e in tau phosphorylated at Thr212 was detected in old Tc1 hippocampus
least significant difference [LSD] p  0.017; n  8) and also old Tc1
o significant increase in tau phosphorylated at Thr212 was detected in the
months of age) (n  7). No significant increase in phospho-tau detected
h wild type littermate control hippocampus (n  9–10). Error bars showpus of a
sing ant
anti-to
mpared
months
) and n
xed fac
tau) sig
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ntrol (
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828.e36 O. Sheppard et al. / Neurobiology of Aging 33 (2012) 828.e31–828.e44phorylation. Phosphorylation of tau is a dynamic process
nd phosphate groups can be removed from the protein
y the action of a number of phosphatases. In particular
rotein phosphatase 2A (PP2A) and protein phosphatase
PP1) have a major role in regulating the phosphorylation
f tau (Goedert et al., 1992; Liu et al., 2005; Matsuo et
l., 1994; Papasozomenos and Su, 1995). The expression
f the PP2A catalytic subunit (PP2cat) is dramatically
ecreased in the brains of people who have DS and AD
nd may contribute to disease pathogenesis (Liang et al.,
008). We investigated the abundance of the PP2A cat-
lytic subunit, PP2A scaffold subunit (PR65/A) and PP1
atalytic (PP1) subunit in the brains of Tc1 mice. The
evel of the phosphatase subunits, detected by Western
lot, was the same in the hippocampus of young and old
c1 and wild type littermate control mice (Supplemen-
ary Fig. S4, and Table S1). Similarly no difference in the
mount of PP1, PP2Acat, or PR65/A was observed in the
ortex of aged Tc1 mice compared with wild type litter-
ate control animals (Supplementary Fig. S4). These
ata suggest that the Hsa21 gene or genes required to
odify the expression of PP2Acat may not be function-
lly trisomic in the Tc1 mouse model.
.3. The expression of DYRK1A is elevated in the
ippocampus and cortex of Tc1 mice
Trisomy of the kinase DYRK1A has been previously
linked to the hyperphosphorylation of tau in people with
Fig. 2. Tau is aberrantly phosphorylated at threonine 212 in the cortex of
by Western blot of total cortical protein lysates using anti-phospho-tau ant
loaded per lane and anti-total tau and -actin antibodies were used as co
ample and compared with the phospho-tau/total-tau ratio detected in the
ignificant increase in tau phosphorylated at Thr212 was detected in old Tc
ortex (LSD p  0.04; n  10). No significant increase in phospho-tau det
uploid control cortex (n  7–10). Error bars show standard error of theDS. The Tc1 mouse model of DS carries a copy of human mDYRK1A in addition to the endogenous mouse Dyrk1A gene
and thus the model is trisomic for this gene (Supplementary
Fig. S5). Expression of mouse and human DYRK1A RNA
transcripts can be detected in the brains of Tc1 adult mice
(Fig. 3A and B). AD-related tau pathology is particularly
prominent in the hippocampus and cortex and DYRK1A is
expressed in both these regions in the adult mouse brain
(Braak and Braak, 1991; Martí et al., 2003). To determine if
elevated DYRK1A may contribute to the observed phos-
phorylation of tau in Tc1 mice, we investigated the abun-
dance of this key protein in the hippocampus and cortex. An
increase in DYRK1A signal, normalized to -actin or
GAPDH, was detected by Western blot in both the hip-
pocampus and cortex of young adult and old Tc1 mice
compared with wild type, age-, sex-, and litter-matched
control animals (Fig. 3C–F, Supplementary Table S1)
(ANOVA genotype F(1,47)  723.076; p  0.000, LSD
ost hoc young hippocampus p  0.028, young cortex p 
.004, old hippocampus p  0.041, old cortex p  0.000).
his increase in protein level is consistent with trisomy of
YRK1A in the Tc1 mouse model and is similar to the
ncrease in expression in the brains of adults with DS (Liu
t al., 2008; Wegiel et al., 2008). Thus despite the clear
levation in DYRK1A expression in the Tc1 hippocam-
us in young mice, no elevation in tau phosphorylation is
bserved. We also observe no significant change in the
mount of DYRK1A in young compared with old Tc1
ice or young compared with old control mice (Supple-
c1 mice. The abundance of phosphorylated forms of tau was investigated
Thr212 (A), AT8 (B), and PHF1 (C). Equal amounts of total protein were
A–C). Relative phospho-tau/total-tau signal was determine for each Tc1
ed littermate nontranschromosomic control. Post hoc tests showed that a
x (20 months of age) compared with matched wild type littermate control
y AT8 or PHF1 was detected in aged or young Tc1 cortex compared withaged T
ibodies
ntrols (
match
1 corte
ected bentary Fig. S6).
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0.000). Error bars show standard error of the mean.
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altered in old Tc1 mice
In other mouse models of Hsa21 trisomy, Ts65Dn and
Ts1Cje, and mouse models of DYRK1A overexpression,
significant aberrant phosphorylation of tau at PHF1 and
AT8 sites has been observed (Liu et al., 2008; Ryoo et al.,
2007; Shukkur et al., 2006). Aberrant phosphorylation of
tau is mediated by a number of kinases, including CDK5
(Noble et al., 2003; Plattner et al., 2006). Elevated abun-
dance of CDK5 has been previously reported in adult hip-
pocampus of an alternative mouse model of DS (Pollonini et
al., 2008). Thus to understand the relatively restricted pat-
tern of aberrant tau phosphorylation observed in an aged
Tc1 model, we studied CDK5 level in the brains of old
mice. We observed no significant alteration in the amount of
CDK5 in the hippocampus or the cortex of old Tc1 mice,
compared with wild type littermate control animals (Sup-
plementary Fig. S7). The activity of CDK5 is regulated by
binding to the neuronal specific cofactor p35/p25 (Tsai et
al., 1994). p25 is a cleavage product of p35, it is more stable
than its parent protein and hence a more potent activator of
CDK5 activity (Patrick et al., 1999). Elevated p25/p35 ra-
tios have been reported to occur in AD patients (Patrick et
al., 1999; Tseng et al., 2002) and increased expression of
p25 is linked with aberrant phosphorylation of tau (Noble et
al., 2003; Plattner et al., 2006). We observed no increase in
p35 signal in aged Tc1 cortex or hippocampus. We detected
very low levels of p25 in all samples studied and observed
no elevation of p25/p35 ratio in old Tc1 mice compared
with controls (Supplementary Fig. S7). These data sug-
gested that in old Tc1 mice the pattern of aberrant phos-
phorylation of tau is not mediated by a change in CDK5
level or activity.
3.5. GSK-3 is aberrantly phosphorylated in old but not
young Tc1 mice
In vitro phosphorylation of tau by DYRK1A primes the
protein for further phosphorylation by the kinase GSK-3
(Liu et al., 2008; Woods et al., 2001). Our data suggest that
this process does not occur readily in old Tc1 mice. To
investigate this further we determined the amount and phos-
phorylation status of GSK-3 in the aged Tc1 brain. No
significant change in the level of this key kinase was ob-
served in the brains of Tc1 mice (Fig. 4A, D, and G, and
Supplementary Fig. S8). GSK-3 is constitutively active,
nd kinase activity has been correlated with phosphoryla-
ion of GSK-3 Tyr216 (Hughes et al., 1993). No difference
n phosphorylation of GSK-3 at Tyr216 was observed in
ld Tc1 mice compared with wild type littermate control
nimals (Fig. 4B, E, and H). Activity of GSK-3 can be
significantly inhibited by phosphorylation of N-terminal
Ser9, which when phosphorylated prevents substrate access
to the catalytic kinase site (Cohen and Frame, 2001; Suther-Fig. 3. The expression of DYRK1A is elevated in the brains of Tc1 mice
compared with wild type littermate control mice. The expression of
mouse Dyrk1a and human DYRK1A transcript in Tc1 mouse brain was
confirmed by RT-polymerase chain reaction (PCR) on total brain RNA
from young Tc1 mice (2 months of age, n  3). Primers that cross-react
with both human and mouse Dyrk1A transcript product size 235 base
pairs (A and B) were multiplexed with either specific for mouse Dyrk1a
hat produce a 793-base pair product (A) or primers specific for human
YRK1A that produce a 621-base pair product (B). The amount of
YRK1A protein in the hippocampus and cortex of Tc1 mice was
uantified by Western blot of total protein lysates using anti-DYRK1A
ntibody 7D11, which is predicted to recognize both the human and
ouse form of the protein (D–F). Equal amounts of total protein were
oaded per lane and anti--actin and GAPDH antibodies were used as
ontrols for total protein amount per lane (F) and (G). Relative
YRK1A/-actin signal was determined for each Tc1 sample and
compared with the signal for the matched wild type littermate control.
An increase in DYRK1A was detected in the hippocampus and cortex
of young (2 months of age) and old (20 months of age) Tc1 mice
compared with wild type littermate control mice (analysis of variance
[ANOVA] genotype F(1,47)  723.076; p  0.000; post hoc least
significant difference [LSD] young hippocampus, p  0.028, young
cortex, p  0.004, old hippocampus, p  0.041, and old cortex, p land et al., 1993). In the cortex and hippocampus of aged
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GSK-3 at Ser9 compared with control animals (Fig. 4C
nd F) (ANOVA genotype  age F(1,45)  5.482; p 
Fig. 4. Phosphorylation of glycogen synthase kinase3- (GSK-3) at serin
f total GSK-3 and GSK-3 phosphorylated at Ser9 and Tyr216 was inve
rotein lysates, from old (A–F) and young (G–I) Tc1 mice and matched wi
ane and anti--actin antibody signal was used as a control for amount of to
n Tc1 samples, and compared with age- and sex-matched nontranschrom
as detected in old (20 months of age) hippocampus (n  10) (A), old (2
n  7) (G). Phospho-GSK-3 signal was normalized to total GSK-3 sig
control signal. No significant difference in GSK-3 phosphorylated at T
hippocampus (n  10) (B), old (20 months of age) cortex (n  6) (E), or y
phosphorylated at Ser9 was detected in old (20 months) Tc1 brain (analys
oc least significant difference (LSD) tests significant increases in signal
ge) cortex (p 0.003) (F) compared with age- and sex-matched control sa
n young Tc1 hippocampus (n  7) (I). Error bars show standard error of0.024, LSD post hoc hippocampus p  0.011, cortex p  l0.003). This change in phosphorylation suggests that
GSK-3 activity may be decreased in both the hippocampus
nd cortex of old Tc1. This may contribute to the relatively
ncreased in the hippocampus and cortex of old Tc1 mice. The abundance
by Western blot of total hippocampal (A–C) and (G–I) and cortical (D–F)
littermate control animals. Equal amounts of total protein were loaded per
tein loaded (A–I). Total GSK-3 signal was normalized to GAPDH signal
control signal. No significant difference in total GSK-3 in Tc1 samples
ths of age) cortex (n  7) (D), or young (2 months of age) hippocampus
c1 samples, and compared with the respective matched littermate euploid
was detected in Tc1 compared with controls in old (20 months of age)
months of age) hippocampus (n  6) (H). A significant increase GSK-3
ariance [ANOVA] genotype  age F(1,45)  5.482; p  0.024) by post
tected in aged Tc1 hippocampus (p  0.011) (C) and old (20 months of
o significant increase in phosphorylation of GSK-3 at Ser9 was detected
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that overexpress DYRK1A. Interestingly, no increase in
phosphorylation of GSK-3 Ser9 is observed in young adult
c1 hippocampus (Fig. 4I). Therefore, the altered phosphor-
lation of GSK-3 caused by trisomy of Hsa21 in the Tc1
mouse model is an age-dependent phenotype.
3.6. AKT is aberrantly phosphorylated in old Tc1 mice
GSK-3 Ser9 is not located at a consensus DYRK1A
phosphorylation site, and there is no evidence to suggest
that DYRK1A can directly phosphorylate GSK-3 (Himpel
t al., 2000). Thus, the observed alteration of phosphoryla-
ion of GSK-3 Ser9 is likely to be mediated by other
inases. AKT is known to target the GSK-3 Ser9 site
(Cross et al., 1995); activity of AKT is up-regulated by
phosphosphorylation at Ser473 (Alessi et al., 1996) and an
increase in phosphorylated AKT has been reported to occur
in the Ts65Dn and Ts1Cje mouse models of Hsa21 trisomy
(Siarey et al., 2006; Siddiqui et al., 2008). We investigated
if phosphorylation of AKT at Ser473 is altered in the brain
of old and young Tc1 mice, as this may contribute to the
change in phosphorylation of GSK-3 observed. In the
cortex an increase in phosphorylated AKT signal was ob-
served in old Tc1 mice compared with age- and sex-
matched controls (Fig. 5D) (ANOVA genotype F(1,54) 
4.975; p  0.030; post hoc LSD old Tc1 cortex compared
with age-matched sample, p  0.013). This alteration may
contribute to the observed change in phosphorylation of
GSK-3 Ser9 in old Tc1 mice. No difference in the abun-
ance of total AKT was observed in either the cortex or
ippocampus of old Tc1 mice (Fig. 5A and C). However we
id observe a significant increase in total AKT in young Tc1
ippocampus compared with control samples (ANOVA ge-
otype F(1,47)  4.570; p  0.038; LSD post hoc, p 
.024). In the hippocampus of young Tc1 mice no signifi-
ant increase in AKT phosphorylated at Ser473, relative to
otal AKT, could be detected (Fig. 5E).
. Discussion
People who have DS have an elevated risk of developing
D but the mechanism underlying this phenotype is not
ully understood. Hyperphosphorylation of tau is associated
ith the development of AD in people with and without DS;
ere we study whether trisomy of chromosome 21 genes
lters the abundance of key regulators of tau phosphoryla-
ion and the phosphorylation state of tau, in a unique tri-
omic model of DS that carries a copy of Hsa21. The data
resented here suggests that trisomy of Hsa21 genes leads to
berrant phosphorylation of tau at one site (Thr212) in an
ge-dependent manner but that this does not trigger the
ormation of NFT in the Tc1 mouse model. Furthermore, we
how Hsa21 trisomy also causes the aberrant phosphoryla-
ion of AKT and GSK-3, which may lead to a decrease in
SK-3 activity in the brains of old trisomic mice, high-lighting a novel pathway through which Hsa21 trisomy may
interact with aging mechanisms. The Tc1 mouse model is
not functionally trisomic for APP (personal communication,
S. Gribble, Wellcome Trust, Sanger Institute, and Supple-
mentary Fig. S1). Thus the aberrant phosphorylation ob-
served occurs independently of an extra copy of this impor-
tant AD-associated gene; notably overexpression of mutant
forms of APP promotes tau hyperphosphorylation (Gotz et
al., 2010). Our data suggest that the activity of DYRK1A
and other kinases, including AKT and GSK-3, maybe
important to the phosphorylation status of tau in Hsa21
trisomic models.
The tau site aberrantly phosphorylated in the aged Tc1
mice has been previously shown to be targeted by the Hsa21
kinase DYRK1A (Liu et al., 2008; Ryoo et al., 2007; Woods
et al., 2001). Here we show that expression of this kinase is
upregulated in our mouse model, consistent with the change
observed in the brains of people with DS (Dowjat et al.,
2007; Liu et al., 2008; Lockstone et al., 2007; Wegiel et al.,
2008). Previous studies have demonstrated a correlation
between DYRK1A expression level and kinase activity (Liu
et al., 2008), suggesting that increase DYRK1A kinase
activity occurs in the brains of Tc1 mice. We found that the
increase in DYRK1A protein was similar in young and aged
animals, indicating that aging does not modify the effect of
trisomy on DYRK1A expression in vivo. However, in
young animals the increase in DYRK1A in the hippocam-
pus is not correlated with an increase in aberrant tau phos-
phorylation suggesting the young trisomic brain may be
protected from accumulating this potentially harmful form
of tau. Many processes are known to be important to the
formation of aberrantly phosphorylated tau; including the
accumulation of amyloid, enhanced kinase activity, and
decreased phosphatase activity (Gotz et al., 2010); in young
mice these processes may be efficiently regulated so as to
prevent the accumulation of aberrantly phosphorylated tau.
Aberrant phosphorylation of tau at Ser202 occurs in mice
that overexpress DYRK1A (Ryoo et al., 2007). Although
DYRK1A can phosphorylate tau at serine-202, in vitro, the
efficiency of this reaction is low compared with that of
Ser212 (Ryoo et al., 2007). In this study we do not observe
a significant increase in tau phosphorylated at 202/205 as
detected by AT8 in aged Tc1 brain. This may occur because
the total level of DYRK1A in our trisomic model is insuf-
ficient to cause elevated phosphorylation at this site. Alter-
natively, factors other than DYRK1A may contribute to the
phosphorylation of tau at this site, and may be differentially
regulated in the Tc1 mice compared with other models.
Previous experiments have suggested that the increased
activity of DYRK1A primes tau for further phosphorylation
by GSK-3 at a number of sites (Woods et al., 2001). Here
we show an increase in phosphorylation of GSK-3 at a site
(Ser9) that inactivates the kinase’s activity; this may con-
tribute to the limited number of tau phosphorylation sites at
which phosphorylation is altered in the Tc1 model. Alter-
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trisomic for less than 60% of Hsa21 genes exhibit increased
phosphorylation of tau at a number of sites, including those
that were not significantly changed in this study (Liu et al.,
2008; Ryoo et al., 2007). Consistent with our results phos-
phorylation of GSK-3 Ser9 is not altered in young Ts1Cje
ice that model some aspects of DS (Shukkur et al., 2006).
hosphorylation at this site has not been previously studied
n aged mouse models of DS, but elevated phosphorylation
f GSK-3 Ser9 occurs in the brains of aged people with
S (Swatton et al., 2004) and thus the Tc1 mouse provides
model to further investigate this important phenotype.
Aberrant phosphorylation of tau at Thr212 was observed
n Tc1 brains from mice that were aged 20 months but no
uch change was observed in young mice. Aging is the
ingle greatest risk factor for the development of AD (Evans
t al., 1989); aberrantly phosphorylated tau has been re-
orted in aged people who do not have AD and the extent of
au deposition correlates with age (Buee et al., 2000; Dela-
ourte et al., 1999). Age-dependent aberrant phosphoryla-
ion of tau has also been reported in rodent models (Plattner
t al., 2006). Numerous different mechanisms have been
uggested to mediate the effect of aging on tau phosphory-
ation; including the influence of changes in insulin signal-
ng on GSK-3 activity; the effect of deregulation of cal-
cium signaling on CDK5 activity; the role of mitochondrial
decline, and oxidative stress (Hernández and Avila, 2008;
Mandelkow et al., 1992; Swerdlow and Khan, 2009; Yu et
al., 2009). An increase in GSK-3 activity is observed in
aged rats (Lee et al., 2006). The data presented here suggest
that trisomy of Hsa21 may modulate the effect of aging on
GSK-3 activity.
GSK-3 also has a role in neuronal development and
survival and has been implicated in a number of neurolog-
ical disorders (Beasley et al., 2001; Cowper-Smith et al.,
2008; Hooper et al., 2008; Jope and Roh, 2006). Inhibitors
of GSK-3 have been shown to help protect neurons against
neurotoxic stimuli and an increase in GSK-3 expression
eportedly increases apoptosis (Chin et al., 2005; Saito et
l., 2010). The altered phosphorylation of GSK-3 ob-
erved in the Tc1 mice may be neuroprotective. There is
uch interest in whether GSK-3 inhibitors can be used as
therapeutic tool for AD, because of the link between
SK-3 activity and tau phosphorylation (Hooper et al.,
2008; Muñoz-Montaño et al., 1997). However, there is no
general consensus as to whether and how GSK-3 activity
s altered in AD patients (Blalock et al., 2004; Hye et al.,
005; Leroy et al., 2007; Pei et al., 1997; Swatton et al.,
004). The data presented here suggest that models of tri-
with the respective matched littermate control signal. A significant increase
in AKT phosphorylated at Ser473 was detected in old (20 months) Tc1
cortex (ANOVA genotype F(1,54)  4.975; p  0.030; post hoc LSD p Fig. 5. Phosphorylation of AKT at serine-473 is increased in the cortex of
old Tc1 mice. The abundance of total AKT and AKT phosphorylated at
Ser473 was investigated by Western blot of total hippocampal (A–B) and
(E–G) and cortical (C–D) and (H) protein lysates, from young (2 months
of age) (E) and (F) and old (20 months of age) (A–D) and (G–H) Tc1 mice
and age- and sex-matched wild type littermate control animals. Equal
amounts of total protein were loaded per lane and anti--actin antibody
ignal was used as a control for amount of total protein loaded (A–H). Total
KT signal was normalized to -actin signal in Tc1 samples, and com-
ared with the respective matched wild type littermate control signal. No
ignificant difference in total AKT in Tc1 samples was detected in old (20
onths of age) hippocampus (n  12) (A) or cortex (n  12) (C). A
ignificant increase in total AKT signal was detected in young hippocam-
us (analysis of variance [ANOVA] genotype F(1,47) 4.570; p 0.038;
east significant difference [LSD] post hoc p  0.024) (E). Phospho-AKT0.013) (D). Error bars show standard error of the mean.
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GSK-3 activity. Inhibition of GSK-3 and aberrant phos-
horylation of tau are also associated with defects in work-
ng and spatial memory (Arendash et al., 2004; Bell et al.,
005; Hu et al., 2009; Tan et al., 2010) and may contribute
o learning deficits in aged Tc1 mice.
GSK-3 is a serine/threonine kinase and is a prominent
member of the Wnt--catenin cell signaling pathway (Hur
and Zhou, 2010; Wu and Pan, 2010). Inactivation of
GSK-3 can be triggered by changes in cell survival or
nsulin signaling (reviewed by Hur and Zhou, 2010); these
ignaling pathways may be modified in DS. A number of
ifferent kinases can phosphorylate GSK-3 Ser9, includ-
ing AKT, ribosomal protein S6 kinase, and S6 kinase (Cross
et al., 1995; Kim and Kimmel, 2000; Sutherland et al.,
1993). Here we show phosphorylation of AKT Ser473 is
enhanced in the brains of old Tc1 mice. Phosphorylation of
AKT activates this kinase and hence may contribute to the
observed change in GSK-3. Altered phosphorylation of
AKT has also been observed in Ts65Dn and Ts1Cje mice,
that model aspects of of DS (Siarey et al., 2006; Siddiqui et
al., 2008).
The identity of the kinase that phosphorylates AKT at
Ser473 is much debated, candidates included the mTOR
protein kinase-rictor complex (Sarbassov et al., 2005). The
region surrounding AKT Ser473 is not similar to the pro-
posed DYRK1A consensus sequence (Himpel et al., 2000),
and thus is unlikely to be a direct target of this kinase. Other
Hsa21 trisomic genes may also contribute to the aberrant
phosphorylation of AKT observed in the brains of old Tc1
mice; indeed overexpression of the Hsa21 encoded SOD1
gene has been linked to increase phosphorylation of AKT at
Ser473 in brain, in the context of stress (Endo et al., 2007;
Noshita et al., 2003). Further investigation is required to
determine the mechanism by which the phosphorylation
AKT is modified in Hsa21 trisomy.
Recently, the expression of DYRK1A has been shown
to exhibit circadian oscillations, with highest levels of
expression occurring midway through the dark period
(Kurabayashi et al., 2010). We note that all tissue sam-
ples presented in this report were collected between hours
1 and 6 of the light cycle, when DYRK1A is half its
maximal level (Kurabayashi et al., 2010). Higher levels
of DYRK1A could magnify or modify the effects ob-
served here, such that more extensive phosphorylation of
tau at Thr212 may occur at night.
5. Conclusions
The Tc1 mouse carries a freely segregating copy of
Hsa21 and is a unique animal model of DS. Here we use this
model to study the influence of Hsa21 trisomy on tau phos-
phorylation in both young adult and aged mice. We show
that in the aged Tc1 brain tau is aberrantly phosphorylated
at Thr212; this phosphorylation site is known to be a target 2of the Hsa21 kinase, DYRK1A. Consistent with this, Tc1
mice are trisomic for DYRK1A and overexpress the protein
n brain throughout adult life. However, an increase in tau
hosphorylated at Thr212 is not detected in young Tc1
nimals. This novel result suggests that the young trisomic
rain is protected from accumulating hyperphosphorylated
au despite the raised level of DYRK1A. Furthermore, in
ontrast to reports from alternative models of DS, aged Tc1
ice do not exhibit significantly increased phosphorylation
f tau at sites other than Thr212. This may result from a
ecrease in GSK-3 activity in the aged Tc1 brain, which
ay counter further aberrant phosphorylation of tau after
riming phosphorylation by DYRK1A. Alterations in the
ctivity of key regulators of tau phosphorylation other than
YRK1A may also occur in people who have DS and could
ontribute to their risk of developing AD.
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